Validation of plasmin-cleaved VWF as a biomarker for microthrombosis in Japanese patients with acute immune-mediated TTP. Open Access

Authors’ contributions

H.E.O., C.T. and K.S. designed the study; H.E.O. performed the experiments; K.S. and M.M. recruited the patients; H.E.O., C.T. K. V., M. M., and K.S. analyzed the data and interpreted the results, H.E.O., C.T. and K.S. wrote the manuscript; all authors read and approved the manuscript.

Funding This work was supported by research grants from the Ministry of Health, Labour and Welfare of Japan (grant number 20FC1024 to M. M.).

Conflict of interest disclosure K.V. received speaker fees from Sanofi and participated in the advisory boards for Takeda. M. M. provided consultancy services for Takeda, Alexion Pharma, and Sanofi; received speaker fees from Takeda, Alexion Pharma, Asahi Kasei Pharma, and Sanofi; and received research funding from Alexion Pharma, Chugai Pharmaceutical, Asahi Kasei Pharma, and Sanofi. K. S. received speaker fees from Sanofi and participated in the advisory boards for Takeda and Alexion Pharma.

Data-sharing statement Data are available from the, corresponding author, Hinde El Otmani (h.elotmani-2@umcutrecht.nl), upon reasonable request.